PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12007790-3	2002	NIH 3T3 cells expressing a hydroxytamoxifen-inducible oncogenic c-Raf-1-oestrogen receptor fusion protein (c-Raf-1-BxB-ER, N-BxB-ER cells) undergo morphological transformation upon stimulation of the Raf kinase.	hydroxytamoxifen	27-43	v-raf-leukemia viral oncogene 1	Mus musculus	64-69	
12007790-3	2002	NIH 3T3 cells expressing a hydroxytamoxifen-inducible oncogenic c-Raf-1-oestrogen receptor fusion protein (c-Raf-1-BxB-ER, N-BxB-ER cells) undergo morphological transformation upon stimulation of the Raf kinase.	hydroxytamoxifen	27-43	v-raf-leukemia viral oncogene 1	Mus musculus	107-112	
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	v-raf-leukemia viral oncogene 1	Mus musculus	14-19	
9563474-1	1998	The selection of NIH 3T3 cells expressing a hydroxytamoxifen-inducible c-Raf-1-estrogen receptor fusion protein (c-Raf-1-BxB-ER) in the absence or presence of the inducer results in dramatic differences in the expression levels of the fusion protein.	hydroxytamoxifen	44-60	v-raf-leukemia viral oncogene 1	Mus musculus	71-76	
9563474-1	1998	The selection of NIH 3T3 cells expressing a hydroxytamoxifen-inducible c-Raf-1-estrogen receptor fusion protein (c-Raf-1-BxB-ER) in the absence or presence of the inducer results in dramatic differences in the expression levels of the fusion protein.	hydroxytamoxifen	44-60	v-raf-leukemia viral oncogene 1	Mus musculus	113-118	
9563474-2	1998	Hydroxytamoxifen-mediated constitutive activation of the Raf signal favors the selection of cells expressing low levels of c-Raf-1-BxB-ER.	hydroxytamoxifen	0-16	v-raf-leukemia viral oncogene 1	Mus musculus	123-128	
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	v-raf-leukemia viral oncogene 1	Mus musculus	94-99	
9464539-4	1998	Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase.	hydroxytamoxifen	121-139	v-raf-leukemia viral oncogene 1	Mus musculus	94-99	
9464539-6	1998	4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER induces the expression of the c-myc gene within 2-6 h. Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling.	hydroxytamoxifen	0-18	v-raf-leukemia viral oncogene 1	Mus musculus	158-163	
9464539-6	1998	4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER induces the expression of the c-myc gene within 2-6 h. Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling.	hydroxytamoxifen	0-18	v-raf-leukemia viral oncogene 1	Mus musculus	199-204	
9464539-6	1998	4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER induces the expression of the c-myc gene within 2-6 h. Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling.	hydroxytamoxifen	0-18	v-raf-leukemia viral oncogene 1	Mus musculus	199-204